Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: A systematic review and meta-analysis

Fertility and Sterility

Volumn 95, Issue 3, 2011, Pages

  Bedaiwy, Mohamed A ^a,b   Abou Setta, Ahmed M ^c   Desai, Nina ^d   Hurd, William ^a   Starks, David ^a   El Nashar, Sherif A ^b   Al Inany, Hesham G ^e   Falcone, Tommaso ^d  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b ASSIUT UNIVERSITY   (Egypt)

^c UNIVERSITY OF ALBERTA   (Canada)

^d LERNER RESEARCH INSTITUTE   (United States)

^e CAIRO UNIVERSITY   (Egypt)

Author keywords

Chemotherapy; gonadotrophin releasing hormone; meta analysis; premature ovarian failure; randomized trial

Indexed keywords

ANTHRACYCLINE; BLEOMYCIN; BUSERELIN; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; FLUOROURACIL; GONADORELIN DERIVATIVE; GOSERELIN; METHOTREXATE; PREDNISONE; PROCARBAZINE; TAMOXIFEN; TAXANE DERIVATIVE; TRIPTORELIN; VINBLASTINE; VINCRISTINE SULFATE;

BREAST ADENOCARCINOMA; BREAST CANCER; CHEMOTHERAPY; COMPARATIVE STUDY; EMBASE; FOLLITROPIN BLOOD LEVEL; HODGKIN DISEASE; HUMAN; INTENTION TO TREAT ANALYSIS; MEDLINE; MENSTRUATION; META ANALYSIS; MULTIPLE CYCLE TREATMENT; OVARIAN RESERVE; OVARY CANCER; OVARY FUNCTION; OVULATION; PARTHENOGENESIS; PREGNANCY RATE; PREMATURE OVARIAN FAILURE; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 79951959330     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2010.11.017     Document Type: Article

References (29)

1. Jemal A, Siegel R,Ward E,Murray T, Xu J, ThunMJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Maltaris T, Seufert R, Fischl F, Schaffrath M, Pollow K, Koelbl H, et al. The effect of cancer treatment on female fertility and strategies for preserving fertility. Eur J Obstet Gynecol Reprod Biol 2007;130:148-55. (Pubitemid 46097248)
3. Sklar C. Maintenance of ovarian function and risk of premature menopause related to cancer treatment. J Natl Cancer Inst Monogr 2005:25-7.
4. Klimm B, Schnell R, Diehl V, Engert A. Current treatment and immunotherapy of Hodgkin's lymphoma. Haematologica 2005;90:1680-92. (Pubitemid 41818990)
5. Olopade OI, Grushko TA, Nanda R, Huo D. Advances in breast cancer: pathways to personalized medicine. Clin Cancer Res 2008;14:7988-99.
6. Kreuser ED, Hetzel WD, Billia DO, Thiel E. Gonadal toxicity following cancer therapy in adults: significance, diagnosis, prevention and treatment. Cancer Treat Rev 1990;17:169-75.
7. Shenns RJ. Gonadal dysfunction. In: DeVita VTJ, Hellman S, Rosenberg SA, editors. Cancer - principles and practice of oncology. Philadelphia: J.B. Lippincott; 1993.
8. Lamar CA, DeCherney AH. Fertility preservation: state of the science and future research directions. Fertil Steril 2009;91:316-9.
9. Porcu E, Venturoli S, Damiano G, Ciotti PM, Notarangelo L, Paradisi R, et al. Healthy twins delivered after oocyte cryopreservation and bilateral ovariectomy for ovarian cancer. Reprod Biomed Online 2008;17:265-7.
10. Meirow D. Fertility preservation in cancer patients using stored ovarian tissue: clinical aspects. Curr Opin Endocrinol Diabetes Obes 2008;15:536-47.
11. Sutcliffe SB. Cytotoxic chemotherapy and gonadal function in patients with Hodgkin's disease: facts and thoughts. JAMA 1979;242:1898-9. (Pubitemid 10219135)
12. Wallace WH, Shalet SM, Tetlow LJ, Morris-Jones PH. Ovarian function following the treatment of childhood acute lymphoblastic leukaemia. Med Pediatr Oncol 1993;21:333-9. (Pubitemid 23152969)
13. Badawy A, Elnashar A, El-Ashry M, Shahat M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 2009;91:694-7.
14. Waxman JH, Ahmed R, Smith D, Wrigley PF, GregoryW, Shalet S, et al. Failure to preserve fertility in patients with Hodgkin's disease. Cancer Chemother Pharmacol 1987;19:159-62. (Pubitemid 17059373)
15. Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. Version 5.0.2. The Cochrane Collaboration, 2009. Available at: http://www.mrc-bsu.cam.ac.uk/cochrane/handbook/. Accessed September 2010.
16. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
17. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58. (Pubitemid 34746062)
18. Gilani MM, Hasanzadeh M, Ghaemmaghami F, Ramazanzadeh F. Ovarian preservation with gonadotropin-releasing hormone analog during chemotherapy. Asia-Pac J Clin Oncol 2007;3:79-83. (Pubitemid 46887755)
19. Giuseppe L, Attilio G, Edoardo DN, Loredana G, Cristina L, Vincenzo L. Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematology 2007;12:141-7. (Pubitemid 46605523)
20. German Breast Group. Prevention of chemotherapy induced ovarian failure with goserelin in BC patients (ZORO). ClinicalTrials.gov NCT00196846, 2010. Available at: http://clinicaltrials.gov/ct2/show/NCT00196846. Accessed November 15, 2010.
21. Gerber B, Stehle H, Ricardo F, Maass D, Fischer N, Sommer HL, et al. ZORO: a prospective randomized multicenter study to prevent chemotherapy-induced ovarian failure with the GnRH-agonist goserelin in young hormone-insensitive breast cancer patients receiving anthracycline containing (neo-) adjuvant chemotherapy (GBG 37). Abstract ID 34455. American Society of Clinical Oncology (ASCO) Annual Meeting. J Clin Oncol, 2009:15s. Available at: http://www.asco.org/ascov2/Meetings/Abstracts. Accessed November 15, 2010.
22. Sverrisdottir A, Nystedt M, Johansson H, Fornander T. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat 2009;117:561-7.
23. Byrne J, Mulvihill JJ, Myers MH, Connelly RR, Naughton MD, Krauss MR, et al. Effects of treatment on fertility in long-term survivors of childhood or adolescent cancer. N Engl J Med 1987;317:1315-21. (Pubitemid 17153013)
24. Blumenfeld Z. Gynaecologic concerns for young women exposed to gonadotoxic chemotherapy. Curr Opin Obstet Gynecol 2003;15:359-70. (Pubitemid 37330379)
25. Blumenfeld Z, Dann E, Avivi I, Epelbaum R, Rowe JM. Fertility after treatment for Hodgkin's disease. Ann Oncol 2002;13(Suppl 1):138-47. (Pubitemid 34567418)
26. Blumenfeld Z, Avivi I, Eckman A, Epelbaum R, Rowe JM, Dann EJ. Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma. Fertil Steril 2008;89:166-73.
27. Blumenfeld Z, Shapiro D, Shteinberg M, Avivi I, Nahir M. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus 2000;9:401-5. (Pubitemid 30487421)
28. Oktay K, Sonmezer M. Questioning GnRH analogs for gonadal protection in cancer patients [letter]. Fertil Steril 2009;92:e4-32.
29. Peccatori F, Demeestere I. GnRH analogue for chemotherapy-induced ovarian damage: too early to say? [letter]. Fertil Steril 2009;92:e4-33.